

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.408
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| May 10, 23 | Needham | maintain | Buy | Buy |
| Feb 10, 23 | Cantor Fitzgerald | maintain | Neutral | Neutral |
| Oct 28, 22 | BTIG | maintain | Buy | Buy |
| Jul 22, 22 | Seaport Global | maintain | Buy | Buy |
| May 12, 22 | Needham | maintain | Buy | Buy |
| Mar 9, 22 | Needham | maintain | Buy | Buy |
| Jan 4, 22 | Needham | maintain | Buy |
Daily · Wilder smoothing
| Buy |
| Nov 12, 21 | Canaccord Genuity | maintain | Buy | Buy |
| Nov 12, 21 | Needham | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 40.96 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 15.22 | Oscillator | Buy |
| Williams %R (14) | -83.02 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.03 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 18.77 (+DI 21.9 / -DI 15.1) | Trend | Neutral |
| EMA 20 | 0.45 | MA | Strong Sell |
| SMA 20 | 0.47 | MA | Strong Sell |
| EMA 50 | 0.46 | MA | Strong Sell |
| SMA 50 | 0.47 | MA | Strong Sell |
| SMA 200 | 0.50 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | AAWH | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.7x | -3.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.9x | EPS est. -0.22 | Elevated |
| Price / Book | -1.0x | 1.4x | Discount |
| Price / Sales | 0.2x | 0.9x | Discount |
| EV / EBITDA | 7.4x | 52.9x | Discount |
| Return on equity | 218.7% | — | Top tier |
| Gross margin | 32.4% | 34.1% | In line |
| Debt / Equity | -7.63 | 0.99 | Conservative |
| Piotroski / Altman Z | 4/9 | Z -0.19 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Dec 16, 24 | Millstreet Capital Management Llc | 10 percent owner | 0 | — | |
| Nov 15, 24 | Millstreet Capital Management Llc | 10 percent owner | S-Sale | 325,000 @ $0.4463 | $145.0K |
| Nov 14, 24 | Millstreet Capital Management Llc | 10 percent owner | 0 | — |
FY2025 · 10-K disclosure
Stock news · updated daily
Seven effect-led formulas built for a specific need state, from deep sleep to date night, begin rolling out across Illinois, Massachusetts, and New Jersey this fall NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH.U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator and consumer packaged goods company, is excited to launch Effin' Tabs, a new line of precision-dosed THC tablets. Effin' Tabs expands the Effin' effect-based product line of edibles and vapes with tablets designed to meet a wide range of consumer needs.
New adult-use dispensary opens through Ascend's social equity partnership program with New Jersey entrepreneur and community advocate Michael Santana NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Ascend Wellness Holdings, Inc. ("AWH," "Ascend" or the "Company") (CSE: AAWH.U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator and consumer packaged goods company, today announced the opening of Ascend of Evesham, a new adult-use cannabis dispensary located at 601 Route 70 in Marlton, New Jersey. Through an agreement permitted under New Jersey law that facilitates expanded investment opportunities for diversely owned businesses in the cannabis industry, Ascend of Evesham will operate independently, with Ascend providing operational support and resources along with local entrepreneur Michael Santana.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) and Ascend Wellness (OTCMKTS:AAWH - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Profitability This table compares Chugai Pharmaceutical and Ascend
The new dispensary expands Ascend's Ohio footprint to seven dispensaries NEW YORK, Oct. 6, 2026 /PRNewswire/ -- Ascend Wellness Holdings, Inc. ("Ascend" or the "Company") (CSE: AAWH) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator and consumer packaged goods company, today announced the opening of its newest dispensary located in Lewis Center, Ohio, at 3812 E Powell Rd, Lewis Center, OH 43035. The dispensary has begun welcoming medical patients and non-medical cannabis customers, with a grand opening to follow on October 9, 2026.
Board authorized to determine ratio and timing; no action needed from stockholders at this time NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH-U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator and consumer packaged goods company, today announced that its stockholders approved an amendment to the Company's Certificate of Incorporation to effect a reverse stock split (the "Reverse Stock Split") of the Company's Class A common stock (the "Class A Common Shares") at the Company's Special Meeting of Stockholders (the "Special Meeting") held virtually on Friday, August 28, 2026. "With this approval in hand, we are better positioned for a listing on a major U.S. exchange.
Ascend Wellness Holdings, Inc. (AAWH) Shareholder/Analyst Call Prepared Remarks Transcript
Ascend Wellness OTCMKTS: AAWH reported second-quarter 2026 net revenue of $126.1 million, up 7.9% sequentially, as new dispensary openings and higher retail sales helped offset pricing pressure and competitive conditions in several markets.
Ascend Wellness Holdings, Inc. (AAWH) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.12 per share a year ago.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -0.06 | -0.05 | Beat 16.7% | $126.1M |
| May 13, 2026 | -0.13 | -0.15 | Miss -15.4% | $116.9M |
| Mar 12, 2026 | -0.12 | -0.24 | Miss -100.0% | $120.5M |
| Nov 10, 2025 | -0.10 | -0.13 | Miss -30.0% | $124.7M |
| Aug 7, 2025 | -0.07 | -0.12 | Miss -71.4% | $127.3M |
| May 12, 2025 | -0.08 | -0.09 | Miss -12.5% | $128.0M |
| DEFA14A | Jul 10, 2026 | 2026-07-09 18:41:50 | View |
| DEF 14A | Jul 9, 2026 | 2026-07-09 17:30:00 | View |
| PRE 14A | Jun 29, 2026 | 2026-06-29 08:30:07 | View |
| 8-K | Jun 25, 2026 | 2026-06-25 16:43:50 | View |
| PREM14A | Jun 25, 2026 | 2026-06-25 16:42:12 | View |
| 10-Q | May 13, 2026 | 2026-05-13 17:15:18 | View |
Proxy statement (DEF 14A) disclosures